Picture EBD Group World of Partnering Opportunities 650x100px

Organisation › Details

AT NewTec GmbH

	Start	2000-11-12 established
	Group	STRÜNGMANN Group (family Strüngmann)
	Industry	venture capital
	Industry 2	LIFE SCIENCES
	Person	Jeggle, Helmut (STRÜNGMANN Group + before Hexal + scine 2009 Apceth Managing Director CFO)
	Person 2	Strüngmann, Thomas (Hexal founder + Biotech investor)

	Region	München (Munich)
	Country	Germany
	Street	6 Rosenheimer Platz
	City	81669 München
		Address record changed: 2014-01-15

Basic data	Employees	n. a.


		Record changed: 2023-12-30

Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

More documents for STRÜNGMANN Group (family Strüngmann)

[1] AiCuris Anti-infective Cures AG. (8/23/23). "Press Release: AiCuris Received 30 Million Euros Milestone Payment from Licensing Partner MSD Following U.S. FDA Approval of Prevymis (letermovir) in Second Indication". Wuppertal....
[2] AiCuris Anti-infective Cures AG. (7/6/23). "Press Release: AiCuris Announces Strategic Shift to Focus Development and Commercialization of Anti-infectives for Immunocompromised Patients". Wuppertal....
[3] AMSilk GmbH. (4/4/23). "Press Release: AMSilk Announces Extension of Series C Financing to EUR 54M". Munich....
[4] AiCuris Anti-infective Cures AG. (4/4/23). "Press Release: AiCuris AG Announces Appointment of Larry Edwards as Chief Executive Officer and Formation of U.S. Subsidiary". Cambridge....
[5] AiCuris Anti-infective Cures AG. (9/1/22). "Press Release: AiCuris Appoints Experienced Business Leader Dr. Sabrina Kuttruff-Coqui as Chief Financial Officer". Wuppertal....
[6] AiCuris Anti-infective Cures AG. (2/9/22). "Press Release: AiCuris and Hybridize Therapeutics Enter Worldwide License Agreement of up to €100M for a Direct-acting RNA-based Therapy against BK Virus". Wuppertal & Leiden....
[7] AiCuris Anti-infective Cures AG. (7/8/21). "Press Release: AiCuris Starts Its First Pivotal Clinical Phase 3 Trial with Pritelivir for the Treatment of Herpes Simplex Virus Infections in Immunocompromised Subjects". Wuppertal....
[8] AiCuris Anti-infective Cures AG. (5/25/21). "Press Release: AiCuris AG Announces Dr. Stefan Oschmann, Former Merck CEO, to Chair the AiCuris Supervisory Board". Wuppertal....
[9] AiCuris Anti-infective Cures GmbH. (6/9/20). "Press Release: Royalty Pharma Acquires Partial Royalty Interest on Prevymis (Letermovir) from AiCuris Anti-infective Cures GmbH". New York, NY & Wuppertal....
[10] 4SC AG. (11/12/19). "Press Release: 4SC AG Secures circa EUR 22.4 Million from a Capital Increase [Not for release in US, Australia, Canada, et al.]". Planegg-Martinsried....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]